....can we calibrate human suffering? How can we measure, or standardize, what people experience and survive in their lives to truly understand where a person is coming from?
I just passed a grumpy woman on the footpath behind the apartment complex where I live. She didn't make eye contact with me, and therefore missed out on my pleasant evening greeting.
As I considered what could possibly be so distracting in her life from meeting my expectations of cordiality, it occurred to me that there is no universal measure of suffering for truly gaining insight into what another person experiences.
Public television covered the war in Yemen and the famine afflicting children. Can we compare these dire conditions with first world hunger and say, yes, children who hunger in Yemen accumulate more human suffering points than children in the US due to severity of conditions?
This isn't to say that suffering is a competition, nor that the clear winner would have any sort of reprieve from their condition....
Disregarding the pronouns, I maintain 'no man's pain is insignificant when it is his own.'
Neuropathic pain arrives without warning like a fantasm from the dark that leaves agony. A persons optimism can be yanked out by the roots, to be replaced by pessimism, because the good times without pain always have the implication, "The pain will return."
I've been proscribed many drugs; none have helped. I've tried many herbs; none have helped.
My story and many similar stories led to the saying, "Shit happens and then you die."
Fortunately, pain is only in our mind, and meditation or self hypnosis can help. In addition, one can eek out a good life between pain sessions. Pain is not generally fatal, so we can learn to minimize its effects. "What doesn't kill you, makes you stronger."
Nice to meat you Swanky. You seem to be coping well. I suspect your pain profile is different from mine. I hope you have times without pain as I do.
"As I considered what could possibly be so distracting in her life from meeting my expectations of cordiality..."
Here's a few things just off the top of my head:
But yeah, the suffering of children in Yemen could have been distracting her too.
A team of University of South Carolina researchers have discovered that the main active cannabis constituent, THC, can suppress the body's immune functions.
Because of its epigenetic influence toward inflammation suppression, cannabis oil can be efficacious in the treatment of autoimmune diseases such as arthritis, lupus, colitis, multiple sclerosis and the like, in which chronic inflammation plays a central role.
Also, CBD oil, which doesn't contain THC, and is sold in most health food stores, also has been shown to cure autoimmune conditions.
CBD Oil Permanently Changed My Autoimmune Condition |[thefix.com]
...that is awesome!!! I spent $284.00 on a tincture in February when I was undergoing multiple surgeries, and it was effective for pain management, but I couldn't afford it, as it only lasted two weeks! Have you heard of Scleroderma?
@Swanky CBD for Scleroderma
Lenabasum Safe and Effective in Diffuse Scleroderma Patients, One–year Trial Data Show. Lenabasum, by Corbus Pharmaceuticals, was shown to be safe, well-tolerated and of benefit to patients treated for one year in a long-term extension of a Phase 2 trial. Scleroderma News, 05/17/2018. (Also see Clinical Trials)
Corbus Wins Expanded U.S. Patent Coverage of Anabasum Therapy for Systemic Sclerosis. Corbus Pharmaceuticals has extended its intellectual property portfolio with a new patent for its investigative cannabinoid–derived drug candidate anabasum to treat inflammatory diseases. Scleroderma News, 11/02/2017. (Also see Clinical Trials)
Emerald Health Pharmaceuticals Granted FDA Orphan Drug Designation for Systemic Scleroderma. Emerald Health Pharmaceuticals Inc. (EHP), which is developing medications based on cannabinoid science, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead molecule, EHP-101, for the treatment of systemic scleroderma. Globe Newswire, 10/20/2017.
New Cannabinoid-based Drug Slows Fibrosis, Blocks Inflammation in Early Scleroderma Study. The drug, VCE-004.8, prevented the formation of fibrosis-promoting myofibroblasts in culture and stopped fibrotic changes in a mouse model of dermal fibrosis. Findings from these pre-clinical studies, while early, are promising and may lead to a new therapy for SSc. Scleroderma News, 03/24/2016.
Expression of the endocannabinoid receptors in human fascial tissue. The endocannabinoid receptors of fascial fibroblasts can contribute to modulate the fascial fibrosis and inflammation. PubMed, Eur J Histochem, 2016 Jun 28;60(2):2643. (Also see Fibroblasts)
Cannabinoids and autoimmune diseases: A systematic review. Cannabinoids are effective as treatment for fibromyalgia and have shown to have anti–fibrotic effect in scleroderma. PubMed, Autoimmun Rev, 2016 Jun;15(6):513-28. (Also see Fibromyalgia)
Pathogenesis of Systemic Sclerosis (SSc). The roles played by other ubiquitous molecular entities in influencing the immune system, vasculature, and connective tissue cells may provide insights into new therapeutic approaches to treat SSc. PubMed, Front Immunol, 2015 Jun 8;6:272.
It is even worse than that I fear, as some things are simply not relateable at all unless or until you experience them.
If you are trying to describe sex to a virgin is is a pointless task, only after they have some experience can you have a viable discussion about sex. You can educate and that is all, a true discourse requires both people to have a grasp of the issue and in some cases you cannot get that.
Then there is individuality, diversity of human presentations. Due to that even things people share might not be relateable. Two women give birth for the first time, both suffer more than they anticipated. One birth is hard and the other easy, do they share an experience, yes, the same experience and opinion of that, hell no.
Ethics tempered with Empathy, we might never know how much a thing hurts, but we can tell it does hurt and act on that.